Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, highlights a radiomics analysis of progression-free survival from the multicenter Italian MeetUro 31 translational study (NCT05782400) in patients with metastatic clear cell renal cell carcinoma (RCC) receiving first-line treatment. Baseline CT-derived radiomic features were used to build a survival model that identified patients at high and low risk of progression. Features reflecting tumor heterogeneity and image intensity were linked to prognosis, supporting radiomics as a potential biomarker approach in this setting. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.